biotech / news / / City A.M.
British drugs giant Astrazeneca has promised to plough £300m into its UK operations, just months after cancelling a nine-figure investment in a new lab.
Astrazeneca has reversed its prior decision and will invest £300m in UK operations.
KEY POINTS
- The revived Cambridge megalab project and £100m for Macclesfield comprise the largest recent UK pharma investment.
- Astrazeneca's investment hinges on a new UK-US trade deal that raised NHS drug prices and secured tariff-free US access.
- The Rosalind Frank building in Cambridge and the Macclesfield site will gain digital drug development capabilities.
- This investment is expected to secure up to 1,000 jobs in Cambridge and Macclesfield.
COMPANIES
Summarized by Newsio from City A.M.. How we summarize →